Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, September 28, 2011 -Astellas Pharma Inc. (Tokyo:4503, “Astellas”) announced that it has decided to discontinue the global development of darexaban maleate (generic name, development...
Astellas Pharma Inc. (Headquarters, Tokyo; President & CEO, Yoshihiko Hatanaka) today announced that the administration of the seasonal influenza HA vaccine ASP7374 (former code: UMN-0502) was...
Astellas Pharma Inc. (“Astellas Pharma”; Headquarters: Chuo-ku, Tokyo; President and CEO: Yoshihiko Hatanaka) and sanofi-aventis K.K. (“sanofi-aventis”; Headquarters: Shinjuku-ku, Tokyo;...
Read more about Transfer of Distribution Rights for Targocid® and Maalox®
Tokyo, Japan, September 7, 2011 - Astellas Pharma Inc. (Tokyo:4503,“Astellas”) announced the donation of three high-standard ambulances to local municipalities in Japan. The numbers of calls...
Read more about Astellas: Donation of Ambulances on First-Aid Day (September 9)
Tokyo & Sapporo, Japan, September 5, 2011 – Evec, Inc. (”Evec”) and Astellas Pharma Inc. (Tokyo:4503, “Astellas”) today announced that they have entered into a license agreement for one...
Read more about Astellas Pharma signs a license agreement with Evec for a fully-human antibody
Tokyo, August 30, 2011 – Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) announced that it has decided to sell the fixed asset listed below. 1． Details of Fixed Asset to Be Sold Asset:...
Follow us
